1 study found for:    s1117
Show Display Options
Rank Status Study
1 Suspended Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine;   Drug: lenalidomide;   Drug: vorinostat

Indicates status has not been verified in more than two years